Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 2-Technical).


Journal

Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410

Informations de publication

Date de publication:
02 2023
Historique:
received: 11 03 2022
revised: 07 07 2022
pubmed: 15 7 2022
medline: 4 2 2023
entrez: 14 7 2022
Statut: ppublish

Résumé

The aim of this initiative was to provide consensus recommendations from a consortium of academic and industry experts in the field of lymphoma and imaging for the consistent application of imaging assessment with the Lugano classification.

Identifiants

pubmed: 35835581
pii: jnumed.122.264124
doi: 10.2967/jnumed.122.264124
pmc: PMC9902846
doi:

Substances chimiques

Fluorodeoxyglucose F18 0Z5B2CJX4D

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

239-243

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : Department of Health
ID : RP-2-16-07-001
Pays : United Kingdom
Organisme : Wellcome Trust
ID : WT203148/Z/16/Z
Pays : United Kingdom

Informations de copyright

© 2023 by the Society of Nuclear Medicine and Molecular Imaging.

Références

Blood. 2021 Apr 29;137(17):2307-2320
pubmed: 33211799
J Nucl Med. 2009 May;50 Suppl 1:122S-50S
pubmed: 19403881
Blood. 2011 Jul 7;118(1):37-43
pubmed: 21518924
J Clin Oncol. 2007 Feb 10;25(5):579-86
pubmed: 17242396
Eur J Nucl Med Mol Imaging. 2013 Sep;40(9):1312-20
pubmed: 23649463
J Nucl Med. 2021 Jan;62(1):37-42
pubmed: 32385164
Eur J Nucl Med Mol Imaging. 2017 Aug;44(Suppl 1):97-110
pubmed: 28411336
Ann Oncol. 2017 Jul 1;28(7):1436-1447
pubmed: 28379322
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54
pubmed: 25452219
Ther Innov Regul Sci. 2021 Nov;55(6):1111-1121
pubmed: 34228319
J Nucl Med. 2010 Dec;51(12):1857-62
pubmed: 21078789
Radiology. 2020 Mar;294(3):647-657
pubmed: 31909700
J Nucl Med. 2021 Aug 1;62(8):1068-1074
pubmed: 33246974
Eur J Nucl Med. 1999 Jan;26(1):39-45
pubmed: 9933660
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
J Clin Oncol. 2016 Oct 20;34(30):3591-3594
pubmed: 27601547
Blood Adv. 2021 May 11;5(9):2375-2384
pubmed: 33944897
J Nucl Med. 2007 Oct;48(10):1626-32
pubmed: 17873129
Blood. 2016 Nov 24;128(21):2489-2496
pubmed: 27574190
Ther Innov Regul Sci. 2021 Nov;55(6):1122-1138
pubmed: 34244987
J Clin Oncol. 2014 Sep 20;32(27):3048-58
pubmed: 25113771
Semin Nucl Med. 2018 Jan;48(1):50-66
pubmed: 29195618
J Nucl Med. 2023 Jan;64(1):102-108
pubmed: 35835580
J Nucl Med. 2012 May;53(5):701-8
pubmed: 22496583
Blood. 2020 Jun 18;135(25):2224-2234
pubmed: 32232481

Auteurs

Fabien Ricard (F)

Relay Therapeutics, Cambridge, Massachusetts; fabienricardmd@gmail.com.

Sally Barrington (S)

King's College London and Guy's and St. Thomas' PET Centre, School of Biomedical Engineering and Imaging Sciences, King's College London, King's Health Partners, London, United Kingdom.

Ron Korn (R)

Adjunct Faculty TGEN/City of Hope and Imaging Endpoints Core Lab, Scottsdale, Arizona.

Guenther Brueggenwerth (G)

Bayer AG, Berlin, Germany.

Judith Trotman (J)

Concord Repatriation General Hospital, University of Sydney, Concord, Australia.

Bruce Cheson (B)

Lymphoma Research Foundation, New York, New York.

Gilles Salles (G)

Department of Medicine, Memorial Sloan Kettering Cancer Center and Weil Cornell Medicine, New York, New York.

Larry Schwartz (L)

Department of Radiology, Columbia University College of Physicians and Surgeons and Radiologist-in-Chief, The New York Presbyterian Hospital, Columbia, New York.

Greg Goldmacher (G)

Merck & Co, Inc., Kenilworth, New Jersey.

Rudresh Jarecha (R)

Deciphera Pharmaceuticals LLC, Waltham, Massachusetts.

Jayant Narang (J)

Takeda Pharmaceutical Company Ltd, Cambridge, Massachusetts.

Florence Broussais (F)

Lymphoma Study Association Research Center LYSARC, Pierre Benite, France Calyx International, Billerica, Massachusetts.

Paul Galette (P)

GSK, Collegeville, Pennsylvania.

Min Liu (M)

Autolus Therapeutics, London, United Kingdom.

Surabhi Bajpai (S)

Calyx International, Billerica, Massachusetts.

Eric Perlman (E)

Perlman Advisory Group LLC, Boynton Beach, Florida.

Julie Gillis (J)

Merigold LLC, Branford, Connecticut.

Ira Smalberg (I)

Saint John's Cancer Institute and Tower Imaging Medical Group, Sherman Oaks, California.

Pierre Terve (P)

KEOSYS Medical Imaging, Saint Herblain, France; and.

Gudrun Zahlmann (G)

QIBA/RSNA, Radiological Society of North America, Oak Brook, Illinois.

Annette Schmid (A)

Takeda Pharmaceutical Company Ltd, Cambridge, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH